Publicaciones en colaboración con investigadores/as de Clínica Universitaria de Navarra (29)

2019

  1. Improvement of appropriate pharmacological prophylaxis in hospitalised cancer patients with a multiscreen e-alert system: a single-centre experience

    Clinical and Translational Oncology, Vol. 21, Núm. 6, pp. 805-809

2018

  1. Insights into venous thromboembolism prevention in hospitalized cancer patients: Lessons from a prospective study

    PLoS ONE, Vol. 13, Núm. 8

2015

  1. Factors influencing the use of thromboprophylaxis in cancer outpatients in clinical practice: A prospective study

    Thrombosis Research, Vol. 136, Núm. 6, pp. 1145-1148

  2. Functional expression of CD137 (4-1BB) on T helper follicular cells

    OncoImmunology, Vol. 4, Núm. 12

  3. Pseudoachalasia secondary to infiltration of the pillars of the diaphragm by an urotelial tumor: Diagnostic approach with endoscopic ultrasound

    Revista Espanola de Enfermedades Digestivas

2014

  1. A population pharmacodynamic model for lactate dehydrogenase and neuron specific enolase to predict tumor progression in small cell lung cancer patients

    AAPS Journal, Vol. 16, Núm. 3, pp. 609-619

  2. Erratum to: Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer

    European Journal of Nuclear Medicine and Molecular Imaging

  3. Identification of tissue microRNAs predictive of sunitinib activity in patients with metastatic renal cell carcinoma

    PLoS ONE, Vol. 9, Núm. 1

  4. Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy

    PLoS ONE, Vol. 9, Núm. 2

  5. Role of [18F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 41, Núm. 11, pp. 2058-2065

2012

  1. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy

    Journal of Immunology, Vol. 189, Núm. 7, pp. 3299-3310

2009

  1. An imbalance in Akt/mTOR is involved in the apoptotic and acantholytic processes in a mouse model of Pemphigus vulgaris

    Experimental Dermatology, Vol. 18, Núm. 9, pp. 771-780

  2. Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer

    World Journal of Gastroenterology, Vol. 15, Núm. 18, pp. 2290-2292

  3. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

    British Journal of Cancer, Vol. 100, Núm. 7, pp. 1111-1119

2008

  1. CT-guided permanent brachytherapy for patients with medically inoperable early-stage non-small cell lung cancer (NSCLC)

    Lung Cancer, Vol. 61, Núm. 2, pp. 209-213

2007

  1. Randomized crossover pharmacokinetic evaluation of subcutaneous versus intravenous granisetron in cancer patients treated with platinum-based chemotherapy

    Oncologist, Vol. 12, Núm. 9, pp. 1151-1155

  2. Stem cells and cancer: elucidating the origin of the cancer stem cell

    Revista de medicina de la Universidad de Navarra, Vol. 51, Núm. 2, pp. 14-17

2006

  1. Transoesophageal endoscopic-ultrasonography-guided 125I permanent brachytherapy for unresectable mediastinal lymphadenopathy

    Lancet Oncology, Vol. 7, Núm. 9, pp. 781-783

2005

  1. Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung center: Two case reports and a review of the literature

    Clinical Lung Cancer, Vol. 7, Núm. 2, pp. 138-140

  2. Assessment of the value of confirming responses in clinical trials in oncology

    European Journal of Cancer, Vol. 41, Núm. 11, pp. 1528-1532